Adam Walsh


Recent Quotes

"DRRX plans to initiate the Phase 2b AH trial in mid-2020."

— Adam Walsh, Stifel (3/4/20)
more >

"While we view the Indivior deal positively as DRRX is able to gain exposure to a late-stage asset in a lucrative deal, we remain focused on Phase 3 PERSIST data expected Q4/17."

— Adam Walsh, Stifel (10/2/17)
more >

"There are good reasons to believe DRRX's upcoming Phase III PERSIST results will be positive and finally pave the road to approval."

— Adam Walsh, Stifel (7/12/17)
more >

Due to permission requirements, not all quotes are shown.